BioTelemetry, Inc. (BEAT): Price and Financial Metrics


BioTelemetry, Inc. (BEAT)

Today's Latest Price: $37.46 USD

2.31 (6.57%)

Updated Apr 2 4:00pm

Add BEAT to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 58 in Medical - Diagnostics/Research

See all "A" rated Strong Buy stocks

BEAT Stock Summary

  • BEAT's current price/earnings ratio is 38.17, which is higher than 87.22% of US stocks with positive earnings.
  • Price to trailing twelve month operating cash flow for BEAT is currently 16.86, higher than 81.54% of US stocks with positive operating cash flow.
  • With a year-over-year growth in debt of -2.48%, Biotelemetry Inc's debt growth rate surpasses 29.43% of about US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Biotelemetry Inc are FNKO, HEAR, HLI, DHX, and COWN.
  • Visit BEAT's SEC page to see the company's official filings. To visit the company's web site, go to www.gobio.com.
BEAT Daily Price Range
BEAT 52-Week Price Range

BEAT Stock Price Chart More Charts


BEAT Price/Volume Stats

Current price $37.46 52-week high $63.24
Prev. close $35.15 52-week low $27.35
Day low $35.01 Volume 374,739
Day high $39.35 Avg. volume 341,063
50-day MA $44.32 Dividend yield N/A
200-day MA $44.27 Market Cap 1.28B

BioTelemetry, Inc. (BEAT) Company Bio


BioTelemetry Inc. provides cardiac monitoring, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services. It operates in three segments: Patient Services, Product, and Research Services. The company is based in Malvern, Pennsylvania.

BEAT Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target:Forecasted Gain:
$37.46$1231.963099%

The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Biotelemetry Inc. To summarize, we found that Biotelemetry Inc ranked in the 92th percentile in terms of potential gain offered. More precisely, our analysis suggests the stock is undervalued by approximately 3114.67% on a DCF basis. In terms of the factors that were most noteworthy in this DCF analysis for BEAT, they are:

  • In the past 4.02 years, Biotelemetry Inc has a compound free cash flow growth rate of 1.64%; that's higher than 95.47% of free cash flow generating stocks in the Healthcare sector.
  • The business' balance sheet suggests that 12% of the company's capital is sourced from debt; this is greater than only 23.02% of the free cash flow producing stocks we're observing.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%3036%
1%3068%
2%3099%
3%3130%
4%3162%
5%3193%

For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as BEAT, try SUPN, MNK, ACHC, HZNP, and LNTH.


BEAT Latest News Stream


Event/TimeNews Detail
Loading, please wait...

BEAT Latest Social Stream


Loading social stream, please wait...

View Full BEAT Social Stream

BEAT Price Returns

1-mo -14.14%
3-mo -20.26%
6-mo -5.46%
1-year -38.18%
3-year 32.13%
5-year 313.47%
YTD -19.09%
2019 -22.47%
2018 99.73%
2017 33.78%
2016 91.35%
2015 16.45%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.7825 seconds.